Acusphere Reports Mixed Top-Line Phase III Results For Imagify
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm contends RAMP-2 pivotal trial results for its cardiac imaging agent will support an NDA filing in the fourth quarter.
You may also be interested in...
Acusphere Future Up In Air After Imagify Fails Before Advisory Panel
Evolving trial design standards and miscommunication with the review division tripped up Acusphere's effort to bring Imagify to market, signaling to competitors in the space that FDA is raising the bar on contrast imaging agents
Acusphere Future Up In Air After Imagify Fails Before Advisory Panel
Evolving trial design standards and miscommunication with the review division tripped up Acusphere's effort to bring Imagify to market, signaling to competitors in the space that FDA is raising the bar on contrast imaging agents
FDA Hints At Additional Trials for Acusphere’s Imagify
Stocks plummet after FDA posts briefing documents detailing extensive safety concerns, and problems with efficacy data, before advisory committee meeting.